세계 알츠하이머병의 치료와 진단 시장 예측 2022-2030년

출판:Inkwood Research(잉크우드 리서치) 출판년월:2022년06월

GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030

치료 및 진단[치료(약물, 질병 단계, 일반 및 브랜드) 진단(요추 천자 검사, 양전자 방출 단층 촬영, 뇌파 검사, 자기 공명 영상, 컴퓨터 단층 촬영, 혈액 검사, 기타 진단)] 지역별

페이지수 235
가격
싱글 사용자 라이센스 USD 2,500
다중 사용자 라이센스 USD 3,000
엔터프라이즈 라이센스 USD 4,500
구성 영문조사보고서

리포트목차    주문/문의    납기/라이센스안내

Sample Request

Global Alzheimer’s Disease Market by Therapeutics & Diagnostics (Therapeutics (Drugs, Disease Stage, Generic & Branded) Diagnostics (Lumbar Puncture Test, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Blood Test, Other Diagnostics)) by Geography

KEY FINDINGS
The global Alzheimer’s disease therapeutics & diagnostics market is anticipated to grow at a 6.61% CAGR during the estimation period between 2022 to 2030. The market growth is accelerated by the rise in the pervasiveness of Alzheimer’s disease, emerging novel diagnostic technologies, and the increasing number of pipeline drugs.
세계 알츠하이머병 치료제 및 진단 시장은 2022년에서 2030년 사이의 추정 기간 동안 6.61% CAGR로 성장할 것으로 예상됩니다.
알츠하이머병의 만연, 새로운 진단 기술의 부상, 파이프라인 약물의 증가로 시장 성장이 가속화되고 있습니다.


MARKET INSIGHTS
Alzheimer’s is a neurodegenerative disease characterized by chronic inflammation and accumulation of beta-amyloid peptides. The elderly usually suffer from Alzheimer’s disease, which gradually damages their thinking skills and memory, eventually destroying their ability to perform the simplest daily tasks. Alzheimer’s disease is the major reason for dementia among the older population. Therefore, the rising geriatric population is a key driver for the global Alzheimer’s disease therapeutics and diagnostics market.
Several novel diagnostics technologies have been discovered for Alzheimer’s disease (AD), including the invention that identifies mutated proteins in subcellular compartments. This invention describes these mutations that lead to the redistribution of crucial cellular organelles.
Furthermore, alteration of organelles distribution can be a powerful diagnostic tool, an assay to screen novel therapeutic compounds for Alzheimer’s disease. This technology’s advantage includes identifying mutated proteins, which are directly involved in the genesis of AD. Thus, there is potential for providing a superior AD diagnosis compared to current diagnostic tests.
REGIONAL INSIGHTS
The global Alzheimer’s disease therapeutics & diagnostics market assessment entails the analysis of Europe, Asia-Pacific, North America, and Rest of World. The Asia-Pacific region is anticipated to propel with the highest CAGR by 2030, owing to the rapidly increasing geriatric population and government initiative to develop medicines to cure AD.
COMPETITIVE INSIGHTS
The competition in the global market is significantly high owing to the presence of generic medicines. Furthermore, strong competition exists among the key players in developing new diagnostics methodologies and treatments. However, the industry is observing meaningful strategic partnerships to enhance market presence.
Some important global players include Merck & Co Inc, Cognoptix Inc, Eli Lilly & Company, Johnson & Johnson, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

관련조사보고서

Inkwood Research에서는 아래의 지역/국가별 시장조사보고서도 출판되어 있습니다.각 보고서의 상세 설명에 대한 문의도 받고 있습니다。

  • ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030
    아시아 태평양 지역의 알츠하이머병 치료 및 진단 시장 예측 2022-2030년
  • EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030
    유럽의 알츠하이머병 치료 및 진단 시장 예측 2022-2030년
  • NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030
    북미의 알츠하이머병 치료 및 진단 시장 예측 2022-2030년
  • UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2028
    미국의 알츠하이머병 치료 및 진단 시장 예측 2022-2028년

목차

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • PARENT MARKET ANALYSIS
    • KEY DRIVERS
      • GROWING GERIATRIC POPULATION
      • RISING PERVASIVENESS OF ALZHEIMER’S DISEASE
      • EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
      • INCREASING PIPELINE DRUGS
    • KEY RESTRAINTS
      • FAILURE OF THE LATE-STAGE DRUGS
      • STRINGENT GOVERNMENT REGULATIONS
      • LACK OF THE AVAILABILITY OF SURROGATE MARKERS
  1. KEY ANALYTICS
    • TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
    • PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
    • IMPACT OF COVID-19 ON ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
    • KEY MARKET TRENDS
    • PORTER’S FIVE FORCES ANALYSIS
      • BUYERS POWER
      • SUPPLIERS POWER
      • SUBSTITUTION
      • NEW ENTRANTS
      • INDUSTRY RIVALRY
    • KEY BUYING CRITERIA
    • SUPPLY CHAIN ANALYSIS
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
  2. MARKET BY THERAPEUTICS & DIAGNOSTICS
    • THERAPEUTICS
      • DRUGS
        • MARKETED DRUGS
        • PIPELINE DRUGS
      • DISEASE STAGE
        • LATE-STAGE: SEVERE AD
        • EARLY/MIDDLE STAGE: MILD TO MODERATE AD
        • PRODROMAL STAGE
      • GENERIC & BRANDED
        • BRANDED
        • GENERIC
    • DIAGNOSTICS
      • LUMBAR PUNCTURE TEST
      • POSITRON EMISSION TOMOGRAPHY
      • ELECTROENCEPHALOGRAPHY
      • MAGNETIC RESONANCE IMAGING
      • COMPUTED TOMOGRAPHY
      • BLOOD TEST
      • OTHER DIAGNOSTICS
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED STATES
        • CANADA
    • EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED KINGDOM
        • GERMANY
        • FRANCE
        • ITALY
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    • ASIA-PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • CHINA
        • JAPAN
        • INDIA
        • SOUTH KOREA
        • INDONESIA
        • THAILAND
        • VIETNAM
        • AUSTRALIA & NEW ZEALAND
        • REST OF ASIA-PACIFIC
    • REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA
  1. COMPETITIVE LANDSCAPE
    • KEY STRATEGIC DEVELOPMENTS
      • MERGERS & ACQUISITIONS
      • PRODUCT LAUNCHES & DEVELOPMENTS
      • PARTNERSHIPS & AGREEMENTS
      • BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
    • COMPANY PROFILES
      • ALLERGAN PLC (ACQUIRED BY ABBVIE)
      • AMARANTUS BIOSCIENCE HOLDINGS INC
      • BAXTER INTERNATIONAL INC
      • BIOGEN INC
      • COGNOPTIX INC
      • EISAI CO LTD
      • ELI LILLY & COMPANY
      • F HOFFMANN-LA ROCHE
      • GE HEALTHCARE
      • JOHNSON & JOHNSON
      • LUPIN LIMITED
      • MERCK & CO INC
      • NOVARTIS AG
      • PFIZER INC
      • SIEMENS HEALTHINEERS AG
      • SUN PHARMACEUTICALS INDUSTRIES LTD
      • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
      • ZYDUS CADILA

LIST OF TABLES  

TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS

TABLE 2: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 3: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 4: GLOBAL THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 5: GLOBAL THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 8: GLOBAL MARKETED DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 9: GLOBAL MARKETED DRUGS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 10: GLOBAL PIPELINE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 11: GLOBAL PIPELINE DRUGS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 13: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 14: GLOBAL LATE-STAGE: SEVERE AD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 15: GLOBAL LATE-STAGE: SEVERE AD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 16: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 17: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 18: GLOBAL PRODROMAL STAGE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 19: GLOBAL PRODROMAL STAGE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 20: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 21: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 22: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 23: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 24: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 25: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 26: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 27: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 28: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 29: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 30: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 31: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 32: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 33: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 34: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 35: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 36: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 37: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 38: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 39: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 40: GLOBAL BLOOD TEST MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 41: GLOBAL BLOOD TEST MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 42: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 43: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 44: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 45: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 46: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 47: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 48: LEADING PLAYERS OPERATING IN NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

TABLE 49: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 50: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 51: LEADING PLAYERS OPERATING IN EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

TABLE 52: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 53: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 54: LEADING PLAYERS OPERATING IN ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

TABLE 55: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 56: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 57: LEADING PLAYERS OPERATING IN REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

TABLE 58: LIST OF MERGERS & ACQUISITIONS

TABLE 59: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 60: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 61: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

LIST OF FIGURES 

FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE

FIGURE 2: KEY MARKET TRENDS

FIGURE 3: PORTER’S FIVE FORCES ANALYSIS

FIGURE 4: KEY BUYING CRITERIA

FIGURE 5: SUPPLY CHAIN ANALYSIS

FIGURE 6: OPPORTUNITY MATRIX

FIGURE 7: VENDOR LANDSCAPE

FIGURE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021

FIGURE 9: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)

FIGURE 10: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021

FIGURE 11: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)

FIGURE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)

FIGURE 13: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021

FIGURE 14: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)

FIGURE 15: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)

FIGURE 16: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)

FIGURE 17: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021

FIGURE 18: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)

FIGURE 19: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)

FIGURE 20: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)

FIGURE 21: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021

FIGURE 22: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)

FIGURE 23: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 24: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 25: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)

FIGURE 26: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 27: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)

FIGURE 28: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)

FIGURE 29: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 30: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 31: CANADA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 32: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 33: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 34: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 35: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: ITALY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 37: BELGIUM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 38: POLAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 39: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 40: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 41: CHINA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 42: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 43: INDIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 44: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 45: INDONESIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 46: THAILAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 47: VIETNAM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 48: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 49: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 50: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)

FIGURE 51: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 52: MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com